Kathleen Neuzil

Kathleen Maletic Neuzil
Alma materUniversity of Maryland, College Park
Johns Hopkins University
AwardsElected to the National Academy of Medicine
Scientific career
InstitutionsUniversity of Maryland School of Medicine
University of Washington School of Medicine

Kathleen Maletic Neuzil is the Director of the Center for Vaccine Development at the University of Maryland School of Medicine. She was elected to the National Academy of Medicine in 2019.

Early life and education

Neuzil studied zoology at the University of Maryland, College Park and graduated summa cum laude in 1983.[1] She was a medical student at Johns Hopkins University, where she was a member of Alpha Omega Alpha. She completed her residency at Vanderbilt University, where she specialised in internal medicine in 1987.[1] She was made a Fellow in infectious disease at Vanderbilt University in 1991.[1] After completing her fellowship, Neuzil started a Master of public health and graduated in 1998.[1]

Research and career

Neuzil works on vaccine development and policy.[2] After her fellowship Neuzil joined the University of Washington School of Medicine, where she served as Director of PATH's Influenza Vaccine Development Project.[3][4] PATH is a Seattle-based nonprofit global health organisation, where Neuzil worked on the rotavirus, human papillomavirus infection (HPV) and Japanese encephalitis vaccines.[5][6] In 2008, Neuzil partnered with Lentigen Corporation to research the pandemic influenza vaccine.[3] Their early work considered the development of Influenza A virus subtype H1N1 and H5N1 virus-like particle pandemic influenza vaccines.[3] Virus-like particle vaccines offer immunogenic, strain-specific recombinant antigens that can be produced at scale.[3] In 2008 Neuzil was made Chair of the Infectious Diseases Society of America Pandemic Influenza Task Force.[1]

In 2015, Neuzil joined the University of Maryland School of Medicine.[4][7]

At the Center for Vaccine Development, Neuzil has developed and deployed vaccines to protect against a range of diseases including typhoid fever, shigellosis, malaria and cholera.[5][8] She has also considered emerging pathogens such as the Zika and Ebola viruses.[5][9][10] The center is also part of the Typhoid Vaccine Acceleration Consortium (TyVAC),[11] a collaboration between the Oxford Vaccine Group, University of Maryland School of Medicine Center for Vaccine Development.[12] The typhoid conjugate vaccine created by TyVAC was demonstrated as a cost-effective strategy to protect people in low- and middle-income countries from typhoid.[13] In 2018, phase 2 clinical trials began on the Influenza A virus subtype H7N9 vaccine.[14]

In 2019, Neuzil and the Center for Vaccine Development at the University of Maryland School of Medicine announced a seven-year $200 million contract with the National Institute of Allergy and Infectious Diseases.[15] The research program tests seasonal influenza vaccines and features clinical trials with populations including pregnant women, children and the elderly.[5] She has spoken about the need for the public to have an influenza vaccine (flu shot), ideally by the end of October.[16][17][18][19]

Alongside her academic positions, Neuzil serves on the World Health Organization Strategic Advisory Group of Experts on Immunization (SAGE) and previously on the advisory group of the Centers for Disease Control and Prevention (CDC).[5] Dr. Neuzil is central to the domestic and global response to COVID-19. As a Co-PI of the NIH-funded Leadership Group for the Vaccine & Treatment Evaluation Unit Network, Dr. Neuzil is part of the strategic team evaluating COVID-19 vaccines and therapeutics in the US.

Awards and honours

Her awards and honours include:

Selected publications

Personal life

Neuzil is married with three children.[23]

References

  1. ^ a b c d e "Neuzil, Kathleen | University of Maryland School of Medicine". www.medschool.umaryland.edu. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  2. ^ Daily Record Staff (2018-04-12). "Kathy Maletic Neuzil". Maryland Daily Record. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  3. ^ a b c d "Lentigen and PATH announce partnership on innovative vaccine for pandemic influenza". www.path.org. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  4. ^ a b "Kathleen M. Neuzil". Rota Council. Archived from the original on 2019-11-09. Retrieved 2019-11-08.
  5. ^ a b c d e "University of Maryland receives landmark contract to research influenza vaccines". EurekAlert!. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  6. ^ "Find resources - PATH Vaccine Resource Library". vaccineresources.org. Retrieved 2019-11-08.
  7. ^ Cohn, Meredith (6 April 2015). "University of Maryland School of Medicine launches Institute for Global Health". baltimoresun.com. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  8. ^ "Vaccines, antimicrobial resistance, and health equity | Department of Medicine | University of Washington". medicine.uw.edu. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  9. ^ "Archived copy". link.videoplatform.limelight.com. Archived from the original on 2024-06-19. Retrieved 2019-11-08.{{cite web}}: CS1 maint: archived copy as title (link)
  10. ^ Cohn, Meredith (4 August 2016). "University of Maryland researchers to test new Zika vaccine". baltimoresun.com. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  11. ^ "About the Typhoid Vaccine Acceleration Consortium". Take on Typhoid. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  12. ^ "International consortium, including OVG, receives $36.9 million grant to fight Typhoid — Oxford Vaccine Group". www.ovg.ox.ac.uk. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  13. ^ Poitras, Colin. "Vaccine Is a Cost-effective Solution for Countries Burdened by Typhoid". Yale School of Public Health. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  14. ^ "H7N9 influenza vaccine clinical trials begin - EPR". European Pharmaceutical Review. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  15. ^ "Center for Vaccine Development Awarded up to $201M to Establish Influenza Clinical Core". globalbiodefense.com. 20 September 2019. Archived from the original on 2019-11-09. Retrieved 2019-11-08.
  16. ^ Sun, Christina Tkacik | The Baltimore. "With flu season on the horizon, a Q&A on this year's vaccine". www.abqjournal.com. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  17. ^ CVD Director Dr. Kathleen Neuzil Appears on MPT's YourHealth, 21 November 2017, archived from the original on 2024-06-19, retrieved 2019-11-08
  18. ^ "Kathleen Neuzil | The Seattle Times". www.seattletimes.com. 22 May 2009. Archived from the original on 2024-06-19. Retrieved 2019-11-08.
  19. ^ Kathleen Neuzil, MD, MPH Gets Vaccinated against Flu to Protect Patients, 9 October 2015, archived from the original on 2024-06-19, retrieved 2019-11-08
  20. ^ "Kathleen Neuzil, M.D., M.P.H." Vanderbilt University. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  21. ^ Daily Record Staff (2018-03-09). "The Daily Record announces Top 100 Women honorees". Maryland Daily Record. Archived from the original on 2019-03-31. Retrieved 2019-11-08.
  22. ^ "UM School Of Medicine's Kathleen Neuzil elected to National Academy of Medicine". EurekAlert!. Archived from the original on 2019-11-08. Retrieved 2019-11-08.
  23. ^ comment, NFID in Vaccines Leave a (2019-05-12). "Sharing the Gift of Health: Happy Mother's Day". National Foundation for Infectious Diseases. Archived from the original on 2024-06-19. Retrieved 2019-11-08.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.